A Phase I Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single Subcutaneous UBT38006 Injection in Healthy Adult Males

NCT07630233 · clinicaltrials.gov ↗

PHASE1

Phase

RECRUITING

Status

53

Enrollment

INDUSTRY

Sponsor class

Conditions

Type 2 Diabetes Mellitus (T2DM)

Interventions

DRUG: UBT38006
DRUG: Placebo
DRUG: Insulin Degludec Injection
DRUG: Insulin Icodec Injection

Sponsor

The United Bio-Technology (Hengqin) Co., Ltd.